Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joshua Hare
University of Miami School of Medicine, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Longeveron
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Hare: 1) is the Chief Scientific Officer (CSO) and interim president, a compensated consultant and advisory board member for Longeveron; 2) is the co-inventor of IP licensed to Longeveron, but not currently used in the Study and 3). holds equity in Longeveron; a company companies whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Mesenchymal stem cell therapy for endothelial dysfunction in diabetes
Project Narrative Myocardial infarction occurs when blood supply to the heart is inadequate, due to the impaired health and function of the blood vessel wall, and this represents the leading cause of death worldwide. Patients with type 2 diabetes are at even higher risk of death and disability from myocardial infarction than non-diabetics. In this proposal, we will explore cellular and molecular mechanisms through which the blood vessel wall can be protected against or healed after injury. Our findings will have implications for developing new therapeutic strategies for myocardial infarction and other related cardiovascular diseases.
Filed on November 30, 2018.
Tell us what you know about Joshua Hare's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joshua Hare filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Longeveron | $250,000 - $299,999 |
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Biscayne Pharmaceuticals | Value cannot be readily determined |
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Biscayne Pharmaceuticals | Value cannot be readily determined |
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Biscayne Pharmaceuticals | Value cannot be readily determined |
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Vestion, Inc | Value cannot be readily determined |
| Joshua Hare | University of Miami School of Medicine | Conflict of Interest | Biscayne Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.